D61.810 Antineoplastic chemotherapy induced pancytopenia

Name of the Condition

• Antineoplastic chemotherapy induced pancytopenia (ICD-10 Code D61.810)

Summary

This condition is characterized by a reduction in all three major blood cell types—red blood cells, white blood cells, and platelets—resulting from antineoplastic chemotherapy. It is a common adverse effect of cancer treatment and can lead to anemia, increased infection risk, and bleeding tendencies.

Causes

The primary cause is the toxic effect of chemotherapy drugs on the bone marrow, which impairs its ability to produce blood cells. This occurs because chemotherapy targets rapidly dividing cells, including those in the bone marrow.

Risk Factors

• Risk factors include the type and dosage of chemotherapy, duration of treatment, pre-existing bone marrow conditions, and individual patient susceptibility. Higher cumulative doses or combination regimens may increase the likelihood of developing pancytopenia.

Symptoms

• Patients may experience fatigue, weakness, pale skin, shortness of breath, easy bruising or bleeding, frequent infections, and dizziness. Symptoms correlate with the severity of blood cell deficiencies.

Diagnosis

Diagnosis is confirmed through a complete blood count (CBC) showing low levels of red blood cells, white blood cells, and platelets. A bone marrow biopsy may be performed to assess marrow function and rule out other causes.

Treatment Options

• Treatment focuses on managing symptoms and supporting blood cell production. This may include blood transfusions, growth factor medications to stimulate cell production, dose adjustments of chemotherapy, or temporary treatment holds.

Prognosis and Follow-Up

Prognosis depends on the underlying cancer, chemotherapy regimen, and response to supportive care. Recovery typically occurs as the bone marrow regains function after chemotherapy ends, but close monitoring is essential to prevent complications.

Complications

• Complications can include severe anemia, life-threatening infections, uncontrolled bleeding, and delayed cancer treatment due to toxicity. In rare cases, prolonged pancytopenia may require additional interventions.

Lifestyle & Prevention

• Patients should avoid activities that increase infection or injury risk, such as contact sports or exposure to sick individuals. Nutritional support and adherence to prescribed medications can help mitigate symptoms.

When to Seek Professional Help

• Seek immediate medical attention for signs of severe bleeding, high fever, or shortness of breath. Regular blood tests during chemotherapy are critical to detect and address pancytopenia early.

Tips for Medical Coders

• Code D61.810 is specific to pancytopenia induced by antineoplastic chemotherapy. Documentation should clearly link the condition to chemotherapy treatment and specify the timing relative to therapy. Ensure the code is not used for pancytopenia from other causes.